Browsing: IBN

OpenAI has decided against releasing a new artificial intelligence system after internal testing revealed problems with how reliably and safely it could operate. The system, known as GPT-6.1 Astra, was designed to work more independently than a conventional chatbot, including browsing the

Surgeons can now identify a brain tumor’s genetic makeup before a patient even leaves the operating table, cutting what used to be an eight-week wait for diagnosis down to about two hours. The Brain Tumor Research Center of Excellence at the

The price of copper declined as the week drew to a close amid rising crude oil prices and a strengthening dollar. These two headwinds exerted downward pressure on most industrial metals. On Thursday alone, LME copper lost 1% to sell

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus “BDBV” outbreak and other Ebola viruses in the Democratic

Silynxcom (NYSE American: SYNX), a manufacturer and developer of ruggedized tactical communication and hearing-protection devices, as well as other gear and accessories, recently announced that it received two consecutive purchase orders from a leading global defense company, totalling around $400,000

This article has been disseminated on behalf of Shelfie-Tech Ltd. and may include paid advertising. 

Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce and engagement, announced a worldwide reseller agreement with Mastercard, authorizing Mastercard to market, offer and sell subscriptions to Rezolve Ai software and SaaS services worldwide on a non-exclusive basis. Mastercard

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) subsidiary MindWave Innovations Inc. USA signed a two-year master maintenance and service agreement with BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet of MindChain for BlockAssure insurance and reinsurance operations.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, received U.S. Food and Drug Administration “FDA” Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home. The designation recognizes the